Last reviewed · How we verify
EUCALYPTUS OIL
EUCALYPTUS OIL is a marketed product primarily indicated for cough relief due to the common cold. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk is the lack of significant revenue data and key trial results, which may limit its market competitiveness.
At a glance
| Generic name | EUCALYPTUS OIL |
|---|---|
| Phase | FDA-approved |
Approved indications
- Cough relief due to common cold
- Muscle and joint pain relief
Common side effects
Key clinical trials
- Boosting Olfactory and Sensory Training Study (BOOST) (EARLY_PHASE1)
- Chemosensory Dysfunction and Recovery in Endoscopic Endonasal Skull Base Surgery (NA)
- Inhaled IAV vs Inhaled Eucalyptus for the Treatment of Nausea With Acute Migraine (NA)
- Essential Oil-Assisted Respiratory Training in Type 2 Diabetic Patients With Lung Infections (NA)
- Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19) (PHASE4)
- Olfactory Function and Delayed Neurocognitive Recovery (NA)
- Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks (PHASE4)
- Olfactory Training on Smell Dysfunction Patients in HK (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EUCALYPTUS OIL CI brief — competitive landscape report
- EUCALYPTUS OIL updates RSS · CI watch RSS